Travere Therapeutics to Present Abstracts on FILSPARI®

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,...

Related Keywords

Japan , Argentina , United States , Orlando , Florida , Buenos Aires , Distrito Federal , American , Jula Inrig , Exchange Commission , American Nephrology Nurses Association , European Commission , Nasdaq , National Symposium In Orlando , World Congress , Travere Therapeutics Inc , National Symposium , Subgroup Analyses , Year Results , Pivotal Phase , Main Foyer , First Line Treatment , Incident Patients , Iga Nephropathy , Preliminary Findings , Clinical Glomerulonephritis , Label Extension , Receptor Occupancy Modeling , Clinical Actions , Pediatric Patients , Selected Proteinuric Glomerular , Novel Non Immunosuppressive Therapy , Humanistic Burdens , Focal Segmental Glomerular Sclerosis , External Controls , Humanistic Burdens Between Patients , Kidney Failure , Treatment Effects , Travere Therapeutics , Important Safety , Endothelin Receptor Antagonists , Upper Limit , Fetal Toxicity , Kidney Injury , Angiotensin System , Acid Reducing Agents , Steroidal Anti Inflammatory Agents , Including Selective , Increasing Serum Potassium , Reproductive Potential , Full Prescribing Information , Private Securities Litigation Reform Act , Markets ,